SAL 0102
Alternative Names: SAL-0102Latest Information Update: 28 Mar 2023
Price :
$50 *
At a glance
- Originator Shenzhen Salubris Pharmaceuticals
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Cardiovascular-disorders in China
- 04 Mar 2019 SAL 0102 is available for licensing as of 21 Feb 2019. http://www.salubris.com/index_en.html
- 21 Feb 2019 Preclinical trials in Cardiovascular disorders in China (unspecified route) prior to February 2019 (Shenzhen Salubris Pharmaceuticals, February 2019)